PCSA — Processa Pharmaceuticals, Inc.

Summary of Processa Pharmaceuticals Q4 2022 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2022, Processa had a cash balance of $6.5 million. Following a $6.4 million capital raise from the sale of shares, the total cash available is approximately $12.9 million, expected to fund operations through Q3 2024.
• Net Loss: The company reported a GAAP net loss of $27.4 million ($1.70 per share) for 2022, up from a loss of $11.4 million ($0.75 per share) in 2021. The increase was attributed to a one-time non-cash impairment of an intangible asset ($7.3 million) and higher clinical trial costs.
• R&D and G&A Expenses: R&D costs rose to $11.5 million (up $4.6 million from 2021), while G&A expenses increased to $8.8 million (up from $4.7 million in 2021), largely due to stock-based compensation.

2. Strategic Updates and Business Highlights

• Focus Shift: The company announced a strategic pivot to concentrate on three next-generation oncology drugs, specifically targeting improved versions of capecitabine, gemcitabine, and irinotecan.
• Regulatory Approach: Processa is leveraging its regulatory science expertise and aligning its drug development strategies with the FDA's Project Optimus initiative, which aims to optimize dosing regimens for oncology drugs.
• Clinical Trials: The company is preparing for a Phase 2b trial for next-generation capecitabine, with a meeting scheduled with the FDA in April 2023 to discuss trial design and dosage regimens.

3. Forward Guidance and Outlook

• Milestones for 2023: Key goals include:
  • Meeting with the FDA to finalize the Phase 2b protocol for capecitabine.
  • Completing the Phase 1b trial for capecitabine and initiating the Phase 2b trial by the end of 2023.
  • Initiating IND-enabling studies for next-generation irinotecan by the end of 2024.
• Investor Engagement: The company plans to enhance visibility and communication with investors and the oncology community.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The significant rise in net loss raises concerns about financial sustainability as a pre-revenue company.
• Stock Performance: Management acknowledged the underperformance of the stock and expressed commitment to strategies aimed at enhancing shareholder value.
• Clinical Trial Risks: The reliance on FDA negotiations for trial designs introduces uncertainty regarding timelines and costs, which may impact future funding and operational strategies.

5. Notable Q&A Insights

• Dosage Optimization: Management emphasized the importance of individualized dosing in upcoming trials, which will be informed by ongoing Phase 1b data.
• Market Potential: The next-generation drugs are expected to target a broad patient population, particularly those who would typically be prescribed existing chemotherapy drugs.
• C-Suite Stock Purchases: Executives were unable to purchase shares recently due to blackout periods related to the capital raise, which raised questions about insider confidence in the stock.

Overall, while Processa Pharmaceuticals is focusing on a promising strategic pivot towards next-generation oncology drugs, it faces significant financial challenges and uncertainties related to clinical trial outcomes and regulatory approvals.